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is a predictor of disease progression and recurrence in patients with primary non-muscle-
invasive bladder cancer (NMIBC). This was a prospective study of 86 patients with newly diag-
nosed NMIBC. The patients were classified by the number of points assigned by the European
Organization for Research and Treatment of Cancer risk tables. The correlation between pro-
gression score, recurrence score, age, mean platelet volume, red blood cell distribution width
and NLR was assessed statistically. The same parameters were compared between the risk
groups. A significant difference in NLR and age values was observed between recurrence and
progression risk score groups. The relationships between NLR and recurrence and progression
risk scores were no longer significant after correcting for the statistical effect of age on scores.
Age was significantly different between groups after adjusting for NLR. Our study revealed that
NLR and age were associated with patient age and bladder tumor progression and recurrence
risk scores. After correcting for age, the significant relationship with NLR was lost, in contrast
to some previous studies. We recommend that patient age should be corrected to avoid
misleading results in NLR studies.
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The overall incidence of urinary bladder cancer (BC) was
about 429,200 cases in 2012. Most (75%) BC is non-muscle
invasive (NMI) at the first diagnosis [Ta, T1, and carcinoma
in situ (CIS)] and usually has a good prognosis. Between 30%
and 80% of cases will relapse as NMI tumors and 1e45% will
progress to muscle invasion (MI) within 5 years [1e3]. The
difficulty of treating non-muscle-invasive bladder cancer
(NMIBC) is to protect the bladder and its function for as long
as possible, accepting the risk of recurrence while mini-
mizing the possibility of progression to muscle-invasive
disease. The European Organization for Research and
Treatment of Cancer (EORTC) risk stratification can be used
to measure these risks [1,3]. The aim has been to divide
patients into risk groups of good, intermediate, and poor
prognosis. After transurethral resection of bladder tumor
(TURBT) and one immediate instillation of chemotherapy,
treatment can be modified according to the patient’s
prognosis. Patients with a good prognosis receive either no
more instillations or intravesical chemotherapy. The
treatment of choice for poor prognosis patients is Bacillus
CalmetteeGue´rin with maintenance. Treatments for
intermediate-risk patients are controversial [4].
According to recent theories, the systemic inflammatory
response induced by cancer causes relative neutrophilia
and lymphocytopenia, producing a protumor inflammatory
state [5]. The neutrophil-to-lymphocyte ratio (NLR), as a
marker of the systemic inflammatory response, has been
studied as a valuable prognostic biomarker in various types
of tumors including BC [6e8]. Among patients with BC, a
high NLR is related to muscle-invasive disease, extravesical
disease, and poorer cancer-specific and overall survival
[8e12]. Nonsteroidal anti-inflammatory drugs have been
suggested to decrease the risk of evolving BC by 19%, sug-
gesting a critical correlation between BC and inflammation
[13]. Mean platelet volume (MPV) is also related with the
pathophysiological characteristics of various types of can-
cer and inflammation [14,15]. Red blood cell distribution
width (RDW) is a strong predictor of all-cause mortality,
including cancer-related death and cancer progression
[16,17].
The aim of our study was to evaluate whether NLR is a
predictor of disease progression and recurrence in patients
with primary NMIBC.
Methods
Study population
This was a prospective study of 86 patients with newly
diagnosed NMIBC (72 men and 14 women) who presented
consecutively at the Urology Clinic of Bozok University
Research Hospital, Yozgat, Turkey. We selected patients
using our laboratory information system database to
retrieve data regarding NLR, RDW, hemoglobin, MPV, and
age. Clinical and pathological data were recorded. The NLR
ratio was calculated using the neutrophil and lymphocyte
values obtained from the complete blood counts. Patients
with newly diagnosed urothelial carcinoma underwent
TURBT at a single institute between 2010 and 2014. Thesepatients were followed up until September 2015. The study
data were collected from 2010 to 2015. All specimens were
reviewed by a pathologist, and the urothelial carcinoma of
the bladder diagnosis was confirmed. Tumors were staged
according to the 2002 American Joint Committee on Cancer
TNM (tumorenodeemetastasis) staging system [18], and
graded according to the 1973 World Health Organization
grading system [19].
The patients were classified by the number of points
assigned by the EORTC risk tables. Patients with a pro-
gression risk score of 0, 2e6, 7e13, and > 13 were cate-
gorized as Group 1, 2, 3, and 4, respectively. Furthermore,
scores of 0, 2e6, and > 6 were considered low, interme-
diate, and high risk for progression, respectively, according
to the European Association of Urology (EAU) guidelines.
Patients with a recurrence risk score of 0, 1e4, 5e9, and >
9 were Groups 1, 2, 3, and 4, respectively. Similarly, 0, 1e9,
and > 9 were low, intermediate, and high risk of recur-
rence, respectively according to the EAU guidelines [20].
A second TURBTwas routinely performed in patients who
had a T1 tumor or the important risk of residual tumor after
the first TURBT of Ta or G3 tumor in initial TURBT. Patients
received postoperative intravesical instillations based on
tumor characteristics, and according to the choice of the
treating urologist. Maintenance chemotherapy or immuno-
therapy was administered to medium- and high-risk pa-
tients according to the selection of treating urologist.
Postoperative follow-up was designed according to EAU
guidelines and the selection of the treating urologist, for
instance, high-risk patients underwent cystoscopy every 3
months for 2 years, and every 6 months in the following
years. Low-risk patients were monitored after 3 months,
and if the result was negative, the next cystoscopy was
planned for 9 months and subsequently once yearly [3].
Recurrence of bladder tumor was defined as the first his-
tologically confirmed tumor relapse in the bladder,
regardless of its stage. Progression of bladder tumor was
defined as an advance in T category from CIS or Ta to T1
(invasion), development of T2 or an increase in grade of
tumor from low to high [21]. The study endpoints were
defined as immunotherapy requirement or T2 disease. The
follow-up average was 29 months.
This study was approved by the Institutional Ethics
Committee of Bozok University. The correlation between
progression score, recurrence score, patient age, MPV,
RDW, and NLR was assessed statistically. Similar parameters
were compared between the recurrence and progression
risk groups.Statistical analysis
ShapiroeWilk’s and Levene’s tests were used to test for
normality and homogeneity of the data. Values are
expressed as frequencies and percentages, mean -
 standard deviation, or median and 25e75th percentiles.
Student t test and one way analysis of variance were used
to compare parametric continuous variables, and the
ManneWhitney U test was used to compare nonparametric
continuous variables. Categorical data were compared
using the c2 distribution. Pearson’s test was used for the
correlation analysis. A multiple linear regression model was
Table 1 Characteristics and follow-up data of patients
with bladder cancer.
Variables of 86 patients Mean SD or n (%)
Age (y) 65.8 12
Sex
Male 72 (84)
Female 14 (16)
NLR 2.64 0.51
MPV (fL) 8.12 1.2
Hemoglobin (g/dL) 14 1.4
RDW (%) 15.8 1.9
Recurrence risk score 5.1 1.3
Progression risk score 7.68 1.9
Pathological stage
Ta 50 (58)
T1 36 (42)
Grading
G1 11 (13)
G2 48 (56)
G3 27 (31)
Concomitant CIS 13 (15)
No. of tumors
1 59 (69)
2e7 18 (21)
 8 9 (10)
Tumor size (mm)
 10 29 (34)
10e30 36 (42)
 30 21 (24)
Tumor morphology
Papillary 68 (79)
Nonpapillary 18 (21)
EORTC recurrence risk
Low 10 (12)
Medium 55 (64)
High 21 (24)
EORTC progression risk
Low 14 (16)
Medium 21 (25)
High 51 (59)
Recurrence
No 50 (58.2)
1st year 25 (29)
After 1 year 11 (12.8)
Progression
No 67 (77.9)
1st year 10 (11.6)
After 1 year 9 (10.5)
EORTCZ European Organization for Research and Treatment of
Cancer; MPVZmean platelet volume; NLRZ neutrophil-to-
lymphocyte ratio; RDWZ red blood cell distribution width;
SDZ standard deviation.
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progression scores. Statistical analyses were performed
using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). A p
value < 0.05 was considered to indicate significance.
Results
The baseline characteristics and follow-up data of the pa-
tients are summarized in Table 1. The mean age of the
patients was 65.8 12 years. NLR was positively correlated
with patient age (pZ 0.018, rZ 0.315), recurrence risk
score (pZ 0.001, rZ 0.421), and progression risk score
(pZ 0.004, rZ 0.375; Figure 1AeC, respectively). Patient
age was positively correlated with recurrence risk score
(pZ 0.018, rZ 0.313), and progression risk score
(pZ 0.001, rZ 0.443; Figure 1D and 1E, respectively). No
other significant correlations were detected. We showed
that NLR increased relative to the increase in risk score in
the comparison of NLR and recurrence risk scores of pa-
tients. Similarly, a significant difference in NLR values was
observed between recurrence risk score groups
(pZ 0.041). Risk score increased significantly with the in-
crease in age (pZ 0.003). No significant differences were
detected between the other variables (Table 2). NLR values
increased with the increase in progression risk scores. In
addition, a significant difference in NLR values was
observed between the groups (pZ 0.042). Progression risk
score increased with the increase in patient age
(pZ 0.001). No significant differences were found between
any other variables (Table 3). The relationships between
NLR and progression and recurrence risk scores were no
longer significant after correcting for the statistical effect
of age on the progression and recurrence risk scores. NLR
did not differ statistically between the recurrence or pro-
gression risk score groups after adjusting for age (pZ 0.229
and pZ 0.146, respectively). Age was significantly
different between the recurrence risk score and progres-
sion risk score groups after adjusting for NLR (p< 0.001 and
p< 0.003, respectively). The results of performed multiple
linear regression also were similar (Tables 4 and 5).
Discussion
We found that NLR was significantly associated with
recurrence risk score, progression risk score, and patient
age. However, the significant differences were lost after
adjusting for age.
NLR has been recommended as a simple systemic in-
flammatory response marker in patients with a variety of
diseases and can be easily obtained from the differential
white blood cell count [22,23]. BC is often related to
chronic or recurrent inflammation, and a high number of
inflammatory cells are found in the tumor field [24]. The
numbers of T lymphocytes and natural killer cells are
significantly lower in patients with invasive bladder carci-
noma than those in patients with superficial carcinoma
[25]. Several inflammatory parameters obtained from blood
tests, including C-reactive protein, NLR, plate-
letelymphocyte ratio, and albumin level are related to
treatment outcomes from primary operable malignancies
[26]. A higher NLR during the preoperative period has beenlinked to a poor prognosis in certain cancers, including that
of the bladder [10,27,28]. Furthermore, several studies
have reported that a high NLR is associated with worse
recurrence-free, disease-specific, and overall survival in
patients with BC and upper urinary tract cancers [12,29].
NLR level is significantly associated with disease
Figure 1. (A) Correlation between age and NLR. (B) Correlation between NLR and recurrence score. (C) Correlation between NLR
and progression score. (D) Correlation between age and recurrence score. (E) Correlation between age and progression score.
NLRZ neutrophil-to-lymphocyte ratio.
330 S. Albayrak et al.
Table 2 Comparison of NLR, MPV and RDW between groups of recurrence risk.
Variables Group 1 (Low risk;
Score 0; nZ 10)
Group 2 (Intermediate risk;
Score 1e4; nZ 24)
Group 3 (Intermediate risk;
Score 5e9; nZ 31)
Group 4 (High risk;
Score > 9; nZ 21)
p*
NLR 1.93 0.3a 2.18 0.4b 2.68 0.5bc 3.17 0.5c 0.041
MPV (fL) 7.88 1.6a 7.97 1.6a 8.38 1a 8.56 1.17a 0.607
RDW (%) 15.6 1a 16.2 1.7a 15.5 1.7a 16.3 2.4a 0.517
Age (y) 45.2 8a 59.9 11ab 68.8 13b 69.9 15b 0.003
Values are expressed as mean standard deviation.
* Different subscripts letters in a row indicate statistically significant difference. Bold values indicate statistically significant (p< 0.05).
MPVZmean platelet volume; NLRZ neutrophil-to-lymphocyte ratio; RDWZ red blood cell distribution width.
Table 3 Comparison of NLR, MPV and RDW between groups of progression risk.
Variables Group 1 (Low risk;
Score 0; nZ 14)
Group 2 (Intermediate risk;
Score 2e6; nZ 21)
Group 3 (High risk;
Score 7e13; nZ 27)
Group 4 (High risk;
Score > 13; nZ 24)
p*
NLR 2.12 0.4a 2.23 0.4a 2.63 0.5ab 3.25 0.6b 0.019
MPV (fL) 7.68 0.7a 7.95 0.9a 8.24 1.3a 8.67 1.7a 0.186
RDW (%) 17.1 1.8a 15.3 1a 15.8 1.6a 15.7 2.5a 0.171
Age (y) 55.8 9a 62.9 12a,b 68.6 13b 71.7 15b 0.001
Values are expressed as mean standard deviation.
*Different subscripts letters in a row indicate statistically significant difference. Bold value indicates statistically significant (p< 0.05).
MPVZmean platelet volume; NLRZ neutrophil-to-lymphocyte ratio; RDWZ red blood cell distribution width.
Table 4 Independent predictors of recurrence risk scores
by multiple linear regression analysis.
Factors B S.E. b t p*
NLR 0.094 0.039 0.301 2.413 0.064
MPV (fL) 0.057 0.393 0.020 0.144 0.886
RDW (%) 0.400 0.293 0.208 1.366 0.178
Age (y) 1.544 0.510 0.439 3.029 0.004
* Bold value indicates statistically significant (p< 0.05).
BZ unstandardized coefficients; bZ standardized coefficients;
MPVZmean platelet volume; NLRZ neutrophil-to-lymphocyte
ratio; RDWZ red blood cell distribution width; SEZ standard
error.
Table 5 Independent predictors of progression risk scores
by multiple linear regression analysis.
Factors B S.E. b t p*
NLR 2.366 0.821 0.396 2.883 0.064
MPV (fL) 0.697 0.633 0.141 1.100 0.276
RDW (%) 0.663 0.471 0.204 1.407 0.166
Age (y) 0.204 0.063 0.386 3.268 0.002
* Bold value indicates statistically significant (p< 0.05).
BZ unstandardized coefficients; bZ standardized coefficients;
MPVZmean platelet volume; NLRZ neutrophil-to-lymphocyte
ratio; RDWZ red blood cell distribution width; SEZ standard
error.
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Elevated preoperative NLR is associated with increased
risks of extravesical tumor extension and disease recur-
rence. Furthermore, a higher preoperative NLR amongpatients undergoing radical cystectomy is associated with
cancer-specific and all-cause mortality [12]. Higher pre-NLR
is an independent risk factor of disease recurrence and
cancer-specific mortality in patients with upper tract uro-
thelial carcinoma treated with radical nephroureter-
ectomy. In addition, an elevated pre-NLR is significantly
associated with worse pathological features and patient
age [31]. According to Li et al [32], the eldest age group has
the highest NLR, and the youngest age group possesses the
lowest NLR. Healthy elderly people have a high NLR [32]. In
our study, we evaluated patient age, NLR, RDW, and MPV
according to the EORTC risk score. Patient age and NLR
were correlated with recurrence risk score and each other.
Patient age and NLR may be related to the recurrence risk
score. Additionally, NLR and age increased significantly
according to recurrence risk group. NLR was no different
between the risk score groups after adjusting for age.
However, age was significantly different in the recurrence
risk score groups after adjusting for NLR. Our results show
that recurrence risk was affected by age, in contrast to NLR
in other studies [12,30,31]. Studies that evaluate recur-
rence risk in patients with BC should consider age as a
factor.
Tumor size, hydronephrosis, and hemoglobin levels in
patients with BC are the most important preoperative
prognostic factors [33]. Hilmy et al [34] advised that the
preoperative systemic inflammatory response is more
nearly related to outcome in patients with BC treated
with radical cystectomy and reported the usefulness of
CRP as an important prognostic factor for disease-specific
survival. A previous study reported that patients with a
higher NLR display relative lymphocytopenia and may
show a poorer lymphocyte-mediated immune response to
malignancy; thus, deteriorating their prognosis and
332 S. Albayrak et al.increasing the potential for tumor progression [35]. The
association between increased preoperative NLR and
cancer-specific mortality outcomes is complex and yet to
be elucidated. A high NLR reflects both a heightened
neutrophil-dependent inflammatory reaction and a
decreased, lymphocyte-mediated, anti-tumor immune
response. Both of these factors may contribute to
aggressive tumor biology, cancer progression, and poor
prognosis [28,36]. Most studies that have evaluated the
relationship between NLR and outcomes after radical
cystectomy reported that a high NLR is related to worse
recurrence-free, disease-specific, and overall survival
rates [8,10,12]. Although Mano et al [30] recommended
that NLR may add prognostic knowledge to presently used
risk stratification tools for recurrence and progression,
more studies are needed to assess whether the NLR
forecasts disease-specific and overall survival in patients
with NMIBC. Nevertheless, within the limitations of an
early-phase study to evaluate markers, our findings sug-
gest that NLR is a potential prognostic marker for pre-
dicting disease recurrence and progression in patients
with NMIBC [37]. Kaynar et al [38] found a significant
relationship between patient age and tumor invasiveness.
Moreover, a correlation analysis revealed a positive cor-
relation between age, tumor invasiveness, and tumor size
NLR [38]. NLR is an important predictor of disease pro-
gression and recurrence. These findings suggest that
pretreatment NLR might potentially serve as a prognostic
marker in patients with NMIBC. Additional prospective
studies with larger cohorts are needed to validate these
findings [30]. Can et al [9] and Ceylan et al [11] reported
that high NLR levels are significantly related with cancer
muscle invasiveness. An elevated NLR is significantly
associated with extravesical disease and worse overall
and cancer-specific survival in a multivariate analysis [8].
Age, female sex, and NLR are predictors of invasiveness by
urothelial carcinoma [9]. Furthermore, high NLR levels are
associated with patient age. Similarly, a higher NLR level
and patient age is associated with worse pathological
features [9,12,31,32]. In the current study, patient age
and NLR were correlated with progression risk score and
with each other. Patient age and NLR may be associated
with the progression risk score. Furthermore, NLR and age
were significantly different between to progression risk
groups, and NLR was no different between progression risk
score groups after adjusting for age. By contrast, age was
significantly different between the progression risk score
groups after adjusting for NLR. These results show that
progression risk is affected by age but not NLR, as in other
studies [8,11,30]. Studies that assess progression risk in
patients with BC should consider age and adjust for its
effect.
In conclusion, our study revealed that NLR was asso-
ciated with patient age and bladder tumor progression
and recurrence risk scores. Similarly, age was associated
with the same scores. After correcting for age, the sig-
nificant relationship with NLR was lost in contrast to
some previous studies. However, age was significantly
different between the progression risk score groups after
adjusting for NLR. We recommend that patient age
should be corrected to avoid misleading results in NLR
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